The estimated Net Worth of Edward W Frykman is at least 565 千$ dollars as of 6 February 2014. Edward Frykman owns over 5,000 units of Arrowhead Pharmaceuticals stock worth over 565,380$ and over the last 20 years Edward sold ARWR stock worth over 0$.
Edward has made over 4 trades of the Arrowhead Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently Edward exercised 5,000 units of ARWR stock worth 50,000$ on 6 February 2014.
The largest trade Edward's ever made was exercising 50,000 units of Arrowhead Pharmaceuticals stock on 7 December 2010 worth over 289,500$. On average, Edward trades about 2,185 units every 55 days since 2004. As of 6 February 2014 Edward still owns at least 27,000 units of Arrowhead Pharmaceuticals stock.
You can see the complete history of Edward Frykman stock trades at the bottom of the page.
Edward's mailing address filed with the SEC is 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH, CA, 92660.
Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over 129,489,075$ worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth 991,784$ . The most active insiders traders include David M Knott、Christopher Richard Anzalone、Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of 868,068$. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth 237,480$.
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include: